Market News & Trends
Nemera Reinforces its Value Proposition With a Refreshing Visual Identity
More modern, our new brand identity truly embodies who we are, how we partner with our customers and ultimately the value we bring to millions…
XOMA Earns $35-Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer
XOMA Corporation recently announced NIS793, an anti-TGFβ monoclonal antibody licensed from the company, has advanced to the Phase 3 development stage, triggering a $35-million milestone…
Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia
Eyenovia, Inc. recently announced the first patient has been enrolled in the company’s second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for…
Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity
Zealand Pharma A/S recently announced the first patient has been dosed in a Phase 1 clinical trial evaluating the amylin analogue, ZP8396 as a potential…
Processa Pharmaceuticals Announces Next- Generation Capecitabine Inhibits DPD in Phase 1b Interim Analysis
Processa Pharmaceuticals, Inc. recently announced the company’s Next-Generation Capecitabine dosage regimen (a combination of PCS6422 administered with capecitabine) successfully inhibited dihydropyrimidine dehydrogenase (DPD), altering the…
Centogene Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases
Centogene N.V. recently announced it has expanded its partnership with Agios Pharmaceuticals, Inc to provide genetic testing and clinical trial support for Agios’ three global,…
Allena Pharmaceuticals Receives Fast Track Designation From FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout & Advanced Chronic Kidney Disease
Allena Pharmaceuticals, Inc. recently announced its orally administered, urate-degrading enzyme, ALLN-346, has received Fast Track designation from the US FDA. ALLN-346 is in Phase 2…
uniQure Announces Latest Positive Recommendation From Data Safety Monitoring Board in Phase 1/2 Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. recently announced the positive recommendation by the independent Data Safety Monitoring Board (DSMB) following a review of safety data from the four patient…
Hyloris Announces Start of Phase 2 Study of Miconazole-Domiphen Bromide Vaginal Cream in Vulvovaginal Candidiasis
Hyloris Pharmaceuticals SA recently announced the first patient has been enrolled in the Phase 2 dose-finding study of Miconazole-Domiphen Bromide (MCZ-DB), a novel dual-mode-of-action vaginal…
Evox Therapeutics Expands Its Exosome Patent Portfolio
Evox Therapeutics Ltd recently announced it has been granted a new European patent, EP3706796, to add to its growing patent portfolio. This patent covers exosomes…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….